Chinese biotechnology start-up AnHeart Therapeutics announced on Wednesday that it has raised approximately RMB100 million (US$14.54 million) in a series A round of financing from the country’s venture capital firm Decheng Capital.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?